Hematology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

BEAM-101 is edited with a next-generation CRIPSR product to mimic single nucleotide polymorphisms that enable persistence of fetal hemoglobin.

Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.

Paul discussed common symptoms and typical treatments for the 2 adverse events.

The study has now dosed 8 patients in total.

Review top news and interview highlights from the week ending November 25, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A marketing authorization application for etranacogene dezaparvovec is currently under review by the EMA.

Omidubicel’s BLA was originally accepted for priority review in August of this year.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The phase 1 clinical trial plans to initiate enrollment in early 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ExCellThera is in the process of the expanding the studies into new trial sites in the United States and Europe.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

Review top news and interview highlights from the week ending November 11, 2022.

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

Recent communication with the FDA suggests that the agency's decision might be delayed past Q1 2023.

A final evidence report suggests a $1.9 million cap for val-rox and a $2.9 million cap for EtranaDez.

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

Review top news and interview highlights from the week ending November 4, 2022.

Data from the first 2 patients were presented at the IWWM 2022 meeting.